tiprankstipranks
GlaxoSmithKline Pharmaceuticals Limited (IN:GLAXO)
:GLAXO
India Market
GLAXO
GlaxoSmithKline Pharmaceuticals Limited
RESEARCH TOOLSreports

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) Stock Forecast & Price Target

Compare
1 Followers
See the Price Targets and Ratings of:

GLAXO Analyst Ratings

Moderate Buy
1Ratings
1 Buy
0 Hold
0 Sell
Based on 1 analysts giving stock ratings to
GlaxoSmithKline
Pharmaceuticals Limited
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GLAXO Stock 12 Month Forecast

Average Price Target

₹2,250.00
▼(-9.07% Downside)
Based on 1 Wall Street analysts offering 12 month price targets for GlaxoSmithKline Pharmaceuticals Limited in the last 3 months. The average price target is ₹2,250.00 with a high forecast of ₹2,250.00 and a low forecast of ₹2,250.00. The average price target represents a -9.07% change from the last price of ₹2,474.55.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1952":"₹1,952","2361":"₹2,361","2770":"₹2,770","2156.5":"₹2,156.5","2565.5":"₹2,565.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2250,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹2.25K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2250,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹2.25K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2250,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹2.25K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1952,2156.5,2361,2565.5,2770],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Sep<br/>2024","9":"Dec<br/>2024","12":"Feb<br/>2025","25":"Feb<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1976.25,1997.3076923076924,2018.3653846153845,2039.423076923077,2060.480769230769,2081.5384615384614,2102.596153846154,2123.653846153846,2144.7115384615386,2165.769230769231,2186.826923076923,2207.8846153846152,2228.9423076923076,{"y":2250,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1976.25,1997.3076923076924,2018.3653846153845,2039.423076923077,2060.480769230769,2081.5384615384614,2102.596153846154,2123.653846153846,2144.7115384615386,2165.769230769231,2186.826923076923,2207.8846153846152,2228.9423076923076,{"y":2250,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1976.25,1997.3076923076924,2018.3653846153845,2039.423076923077,2060.480769230769,2081.5384615384614,2102.596153846154,2123.653846153846,2144.7115384615386,2165.769230769231,2186.826923076923,2207.8846153846152,2228.9423076923076,{"y":2250,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2110.98,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1953.97,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2051.95,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2618.61,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2593.82,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2743.34,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2769.62,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2725.96,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2707.4,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2409.25,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2234.2,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1976.25,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1976.25,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target₹2,250Average Price Target₹2,250Lowest Price Target₹2,250
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering GlaxoSmithKline Pharmaceuticals Limited

Which Analyst Should I Follow If I Want to Buy IN:GLAXO and Sell After:
1 Month
xxx
Success Rate
1/1 ratings generated profit
100%
Average Return
+6.10%
upgraded a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +6.10% per trade.
3 Months
xxx
Success Rate
1/1 ratings generated profit
100%
Average Return
+6.10%
upgraded a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +6.10% per trade.
1 Year
Abdulkader PuranwalaICICI Securities
Success Rate
1/1 ratings generated profit
100%
Average Return
+6.10%
upgraded a buy rating 15 days ago
Copying Abdulkader Puranwala's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +6.10% per trade.
2 Years
xxx
Success Rate
1/1 ratings generated profit
100%
Average Return
+6.10%
upgraded a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +6.10% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GLAXO Analyst Recommendation Trends

Rating
Feb 25
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
total
1
In the current month, GLAXO has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. GLAXO average Analyst price target in the past 3 months is ₹2,250.00.
Each month's total comprises the sum of three months' worth of ratings.

GLAXO Financial Forecast

GLAXO Earnings Forecast

The previous quarter’s earnings for GLAXO were ₹13.60.
The previous quarter’s earnings for GLAXO were ₹13.60.

GLAXO Sales Forecast

Next quarter’s sales forecast for GLAXO is ₹9.72B with a range of ₹9.72B to ₹9.72B. The previous quarter’s sales results were ₹9.49B. GLAXO beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.53% of the time in the same period. In the last calendar year GLAXO has Outperformed its overall industry.
Next quarter’s sales forecast for GLAXO is ₹9.72B with a range of ₹9.72B to ₹9.72B. The previous quarter’s sales results were ₹9.49B. GLAXO beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.53% of the time in the same period. In the last calendar year GLAXO has Outperformed its overall industry.

GLAXO Stock Forecast FAQ

What is IN:GLAXO’s average 12-month price target, according to analysts?
Based on analyst ratings, GlaxoSmithKline Pharmaceuticals Limited’s 12-month average price target is ₹2,250.00.
    What is IN:GLAXO’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for IN:GLAXO, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is GlaxoSmithKline Pharmaceuticals Limited a Buy, Sell or Hold?
        GlaxoSmithKline Pharmaceuticals Limited has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
          What is GlaxoSmithKline Pharmaceuticals Limited’s share price target?
          The average share price target for GlaxoSmithKline Pharmaceuticals Limited is ₹2,250.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is ₹2,250.00 ,and the lowest forecast is ₹2,250.00. The average share price target represents -9.07% Decrease from the current price of ₹2,474.55.
            What do analysts say about GlaxoSmithKline Pharmaceuticals Limited?
            GlaxoSmithKline Pharmaceuticals Limited’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
              How can I buy shares of GlaxoSmithKline Pharmaceuticals Limited?
              To buy shares of IN:GLAXO, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis